

CORRIGENDUM

Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells

S Cutrupi, S Reineri, A Panetto, E Grosso, L Caizzi, L Ricci, O Friard, S Agati, M Scatolini, G Chiorino, AE Lykkesfeldt and M De Bortoli

Oncogene (2012) 31, 4420; doi:10.1038/onc.2012.95

Correction to: *Oncogene* (2012) 31, 4353–4361; published online 16 January 2012; doi:10.1038/onc.2011.627

After the publication of the article, the authors noticed two errors.

First, Legend to Figure 1b was inadvertently kept in the pre-revision form. The legend should read:

Figure 1 (b) Tab2 downregulation restores tamoxifen response in TamR cells. MCF7 wt and TamR cells were transfected with control (white bars) or Tab2 (black bars) siRNA and 48 h later treated with 10^{-8} M E2 alone or plus 10^{-6} M 4OHT. After 24 h, proliferation was measured by 2 h bromo-deoxyuridine incorporation. Data are expressed as the growth ratio in E2 + 4OHT versus E2 alone, and are means \pm s.d. of replicate experiments (MCF7wt and TamR-4.2 $N=4$; TamR-4.1 $N=3$; TamR-8 $N=5$). *Denotes $P<0.05$ (Mann-Whitney U -test). More details are given as Supplementary Figure S2.

Second, Figure 5a referred to 61 instead of 62 patients. The correct Figure 5a is reproduced below. The authors would like to apologize for these mistakes.




Figure 5a.